Bleeding diathesis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 16: | Line 16: | ||
! | ! | ||
|- | |- | ||
| rowspan=" | | rowspan="15" |Platelet disorders | ||
| rowspan="7" |Thrombocytopenia | | rowspan="7" |Thrombocytopenia | ||
| | |Infection-Induced Thrombocytopenia<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span> | ||
<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span> | |||
| | | | ||
|- | |- | ||
| | |Drug-Induced Thrombocytopenia<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span> | ||
<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span> | |||
| | | | ||
|- | |- | ||
| | |Heparin-Induced Thrombocytopenia<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span> | ||
<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span> | |||
| | | | ||
|- | |- | ||
| | |Immune Thrombocytopenic Purpura (ITP)<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span> | ||
<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span> | |||
| | | | ||
|- | |- | ||
| | |Inherited Thrombocytopenia<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span> | ||
<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span> | |||
| | | | ||
|- | |- | ||
| | |Thrombotic Thrombocytopenic Purpura (TTP)<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span> | ||
<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span> | |||
| | | | ||
|- | |- | ||
| | |Hemolytic Uremic Syndrome<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span> | ||
<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span> | |||
| | | | ||
|- | |- | ||
| | |Thromobcytosis<span name="harr_c115s002s003p001"></span><span name="9100800"></span> | ||
<span name="harr_c115s002s003p001"></span><span name="9100800"></span> | |||
|Thrombocytosis in response to acute or chronic inflammation has not been associated with an increased thrombotic risk. In fact, patients with markedly elevated platelet counts (>1.5 million), usually seen in the setting of a myeloproliferative disorder, have an increased risk of bleeding. This appears to be due, at least in part, to acquired von Willebrand disease (VWD) due to platelet-VWF adhesion and removal. | |Thrombocytosis in response to acute or chronic inflammation has not been associated with an increased thrombotic risk. In fact, patients with markedly elevated platelet counts (>1.5 million), usually seen in the setting of a myeloproliferative disorder, have an increased risk of bleeding. This appears to be due, at least in part, to acquired von Willebrand disease (VWD) due to platelet-VWF adhesion and removal. | ||
| | | | ||
|- | |- | ||
| | | rowspan="7" |Qualitative Disorders of Platelet Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | ||
| | |Inherited Disorders of Platelet Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | ||
<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | |||
| | |||
<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | |||
| | | | ||
|- | |- | ||
| | |Acquired Disorders of Platelet Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span> | ||
<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span> | |||
| | | | ||
|- | |- | ||
| | | rowspan="5" |von Willebrand Disease<span name="harr_c115s002s005p001"></span><span name="9100810"></span> | ||
| | |Type 1 | ||
<span name="harr_c115s002s005p001"></span><span name="9100810"></span> | |||
| | |||
|- | |- | ||
| | |Type 2 A | ||
|- | |- | ||
| | |Type 2 B | ||
|- | |- | ||
| | |Type 2 M | ||
|- | |- | ||
| | |Type 3 | ||
|- | |- | ||
| rowspan="2" |Vessel wall disorders | | rowspan="2" |Vessel wall disorders | ||
Revision as of 17:40, 6 August 2018
|
Bleeding diathesis main page |
|
|---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Mehrian Jafarizade, M.D [2]
Overview
Classification
Differential Diagnosis
| Platelet disorders | Thrombocytopenia | Infection-Induced Thrombocytopenia | |
| Drug-Induced Thrombocytopenia | |||
| Heparin-Induced Thrombocytopenia | |||
| Immune Thrombocytopenic Purpura (ITP) | |||
| Inherited Thrombocytopenia | |||
| Thrombotic Thrombocytopenic Purpura (TTP) | |||
| Hemolytic Uremic Syndrome | |||
| Thromobcytosis | Thrombocytosis in response to acute or chronic inflammation has not been associated with an increased thrombotic risk. In fact, patients with markedly elevated platelet counts (>1.5 million), usually seen in the setting of a myeloproliferative disorder, have an increased risk of bleeding. This appears to be due, at least in part, to acquired von Willebrand disease (VWD) due to platelet-VWF adhesion and removal. | ||
| Qualitative Disorders of Platelet Function | Inherited Disorders of Platelet Function | ||
| Acquired Disorders of Platelet Function | |||
| von Willebrand Disease | Type 1 | ||
| Type 2 A | |||
| Type 2 B | |||
| Type 2 M | |||
| Type 3 | |||
| Vessel wall disorders | Metabolic and Inflammatory Disorders | ||
| Inherited Disorders of the Vessel Wall | |||
| Coagulation disorders | Fibrinogen | ||
| Prothrombin | |||
| Factor V | |||
| Factor VII | |||
| Factor VIII | |||
| Factor IX | |||
| Factor X | |||
| Factor XI | |||
| Factor XII | |||
| HK | |||
| Prekallikrein | |||
| Factor XIII | |||
| Hemophilia | Type A | ||
| Type B | |||
| Type C | |||
| Rare diseases | Disseminated Intravascular Coagulation | ||
| Vitamin K Deficiency | |||
| Coagulation Disorders Associated with Liver Failure | |||
| Acquired Inhibitors of Coagulation Factors |